NEW YORK (GenomeWeb) — Eurofins Genomics and AmpTec have agreed to non-exclusively co-market AmptTec's IVT-RNAs globally under a deal announced today.

The co-marketing agreement covers in vitro transcribed single-stranded, double-stranded, and functional synthetic mRNAs that can be used in a variety of applications including in vitro diagnostics of pathogens, rare mutation detection, and companion diagnostics, Eurofins said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.